Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Metabolic Bone Disease > Repaglinide for Sale > Repaglinide API - A Fast-Acting Meglitinide for Type 2 Diabetes Treatment.
Repaglinide API - A Fast-Acting Meglitinide for Type 2 Diabetes Treatment. buy - large image1
Repaglinide API - A Fast-Acting Meglitinide for Type 2 Diabetes Treatment. buy - image1
Repaglinide API - A Fast-Acting Meglitinide for Type 2 Diabetes Treatment. buy - image2
Repaglinide API - A Fast-Acting Meglitinide for Type 2 Diabetes Treatment. buy - image3
Repaglinide API - A Fast-Acting Meglitinide for Type 2 Diabetes Treatment. buy - image4
Repaglinide API - A Fast-Acting Meglitinide for Type 2 Diabetes Treatment. buy - image5

Repaglinide API - A Fast-Acting Meglitinide for Type 2 Diabetes Treatment.

Unit Price: Get Latest Price
CAS No.:

135062-02-1

Grade:

Pharmaceutical Grade

Content:

98.5%

Port:

Qingdao

Brand:

Tianrui

Packaging:

Sealed fiber drum

Price valid (until):

2025-11-12

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

APIs

  • Product Description

  • Seller Information

  • Description


      About  Product   


    Repaglinide (CAS: 135062-02-1) is a high-purity, chiral active pharmaceutical ingredient (API) belonging to the meglitinide class of anti-diabetic agents. As a fast-acting insulin secretagogue, it is specifically designed for postprandial glucose control in type 2 diabetes patients. Manufactured by Hefei TianRui Pharmaceutical under strict cGMP conditions, our Repaglinide API guarantees high chiral purity, excellent stability, and reliable performance for diabetes medication formulations.

    Items Specifications
    Product Name Repaglinide
    CAS Registry Number 135062-02-1
    IUPAC Name (S)-(+)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid
    Molecular Weight 452.59 g/mol
    Solubility It is soluble in methanol, soluble in ethanol, and almost insoluble in water.
    Primary Use Postprandial blood glucose control in type 2 diabetes
    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 1 Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 2
    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 3

    Company Profile

    • Founded: 2014

    • Focus: High-tech enterprise specializing in the development and industrialization of small-molecule pharmaceutical synthesis technology

    • Facilities:

      • Two workshops (TR1 & TR2) with total capacity ≈ 1000 tons/year

      • Reactors: 3000L×15, 2000L×10, and numerous smaller reactors (1000L, 500L, 100L)

      • Ultra-low temperature cryogenic reactor (explosion-proof workshop included)

      • GMP workshop & clean room

    • QC Lab Equipment: GC×2, HPLC×3, UV, IR, KF titrator, etc.

    • Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 4

    • Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 5
    • Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 6


      About  company  


    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 7

    In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

    In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

    In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 8 Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 9

    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 10

    Basic Info
    Product Name:

    Repaglinide

    Other Name:

    Benzoic acid,2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-;Benzoic acid,2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-,(S)-;2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid;Repaglinide;AG-EE 623ZW;Prandin;NovoNorm;(S)-(+)-2-Ethoxy-4-[[[N-[1-(2-piperidinophenyl)-3-methylbutyl]amino]carbonyl]methyl]benzoic acid;AGEE 623;Novolon;Eurepa;(S)-(+)-Repaglinide;GlucoNorm;Europa 0.5;Europa 1;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid;Enyglid

    CAS No.:

    135062-02-1

    Molecular Formula:

    C27H36N2O4

    InChIKeys:

    InChIKey=FAEKWTJYAYMJKF-QHCPKHFHSA-N

    Molecular Weight:

    452.59

    Exact Mass:

    452.59

    EC Number:

    1312995-182-4

    UNII:

    668Z8C33LU

    NSC Number:

    759893

    DSSTox ID:

    DTXSID3023552

    NCI Thesaurus Code:

    C47703

    ATC Code:

    A10BX02|A - Alimentary tract and metabolism

    HScode:

    2933399090

    Characteristics
    PSA:

    78.9

    XLogP3:

    5.9

    Appearance:

    white solid

    Density:

    1.137±0.06 g/cm3(Predicted)

    Melting Point:

    132 °C

    Boiling Point:

    672.9°C at 760 mmHg

    Flash Point:

    360.8ºC

    Refractive Index:

    1.567

    Water Solubility:

    DMSO: 34 mg/mL

    Storage Conditions:

    2-8°C

    Vapor Pressure:

    5E-19mmHg at 25°C

    Toxicity:

    LD50 orally in rats: >1 g/kg (Grell)

    Specific rotation:

    D20 +6.97° (c = 0.975 in methanol); D20 +7.45° (c = 1.06 in methanol)

    Hazard Identification

    Classification of the substance or mixture

    Reproductive toxicity, Category 2

    Reproductive toxicity, Additional category for effects on or via lactation

    Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 3

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H361 Suspected of damaging fertility or the unborn child

    H362 May cause harm to breast-fed children

    H412 Harmful to aquatic life with long lasting effects

    Precautionary statement(s)
    Prevention

    P203 Obtain, read and follow all safety instructions before use.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    P260 Do not breathe dust/fume/gas/mist/vapours/spray.

    P263 Avoid contact during pregnancy and while nursing.

    P264 Wash ... thoroughly after handling.

    P270 Do not eat, drink or smoke when using this product.

    P273 Avoid release to the environment.

    Response

    P318 IF exposed or concerned, get medical advice.

    Storage

    P405 Store locked up.

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    APIs

    Location:

    No.23,lntersection of Fenglehe Avenue and Leiyang Road, Huagang Town,Feixi County, Hefei, Anhui, China.

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    15

    Total Annual Revenue:

    $50 million-$100 million

    Total Employees:

    11-50

    Year of Establishment:

    2014


    About TianRui  


    Hefei TianRui Pharmaceutical Chemical Co., Ltd was founded in 2014 as a high-tech enterprise focused on the development and industrialization of pharmaceutical small molecule synthesis technology. Our workshop and R&D center are located in Hefei HuaGang Provincial Industrial Park, Anhui Province. We are committed to providing professional technical services and commercialization of small molecule specialty APIs, CGMP standard intermediates, and functional pharmaceutical excipients and MRNA vaccine vectors for domestic and overseas well-known pharmaceutical companies.


      Main Events  


    In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.


    In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.


    In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.